ROC analysis of normalised Act_A11 activity with PainOmics versus control serum samples.

<p>The Area Under the Curve (AUC) of 0.51 ± 0.06 indicates this marker is essentially invariant between serum controls versus PainOmics samples, thereby confirming the homogeneity of the various samples received.</p

Test of sample integrity.

<p> Normalised carboxypeptidase activity for PainOmics samples analysed (<i>A</i>) by centre and (<i>B</i>) as a whole PainOmics group versus control serum samples. (Control = 1.0 ± 0.1 versus PainOmics = 1.0 ± 0.2; unpaired t test <i>P</i> = 0.6). Each data point represents an individual patient sample (average of <i>n</i> = 8 replicates).</p

Test of sample preparation.

<p>The activity of the PainOmics samples was analysed by centre (points represent the average activity for each patient (<i>n</i> = 4). These data indicate the homogeneity of serum sample preparation for our analyses. The presence of several outliers from different centres suggest some variation exists between patient samples for this marker.</p

Schematic representation of the validation of personalized SOPs.

<p>Schematic representation of the validation of personalized SOPs.</p

Participating centres of the PainOmics study.

<p>Participating centres of the PainOmics study.</p

DNA concentration before and after validation.

<p>DNA concentrations (mean ± SD) of DNA test samples in duplicate. Dots indicate single DNA samples of Clinical Centres before and after SOP adjustment.</p

Chromatogram of 2-AB labeled N-linked glycans released from the plasma proteins and separated by HILIC-UPLC.

<p>The small vertical bars below the 0 level denote the integration area for each peak, and the major chemical structure present in each glycan group (GP1-GP39) is given above each peak. <b><i>Data points represent medium of at least the duplicate for each samples with the P-values (-log10) for the analysis of associations between plasma glycans and LBP diagnosed at the time of blood collection for glycome analysis</i></b>.</p